Related Experiment Video

Updated: Mar 14, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

A Review of the Clinical Subgroup Analyses From the RE-LY Trial

Rohit Kumar1, Aref M Rahman2, Brian L Henry2

  • 1John H. Stroger, Jr. Hospital of Cook County, Department of Internal Medicine, Chicago, IL.

Reviews in Cardiovascular Medicine
|September 27, 2016
PubMed

Insights

Dabigatran, a novel oral anticoagulant, demonstrated superior stroke prevention compared to warfarin in atrial fibrillation patients. Further analysis of the RE-LY trial is crucial for understanding its efficacy and safety in diverse patient subgroups.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Atrial fibrillation (AF) is a common arrhythmia associated with increased risk of stroke.
  • Direct-acting oral anticoagulants (DOACs) offer an alternative to vitamin K antagonists like warfarin.
  • Dabigatran was the first DOAC approved for stroke prevention in AF.

Purpose of the Study:

  • To evaluate the efficacy and safety of dabigatran compared to warfarin in patients with nonvalvular AF.
  • To explore the performance of dabigatran in specific patient subgroups within the RE-LY trial.

Main Methods:

  • Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
  • Over 18,000 patients with nonvalvular AF and moderate-to-high stroke risk were randomized.
  • Comparison of dabigatran versus warfarin for primary and secondary endpoints.

Main Results:

  • Dabigatran was superior to warfarin in preventing stroke and thromboembolism.
  • Dabigatran was noninferior to warfarin for major bleeding events.
  • Significant differences observed in secondary endpoints between treatment groups.

Conclusions:

  • Dabigatran offers significant benefits for stroke prevention in AF patients.
  • Patient heterogeneity in the RE-LY trial necessitates subgroup analysis for optimal treatment decisions.
  • Understanding subgroup outcomes enhances clinical guidance for anticoagulation therapy.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
688
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
199
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
519
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
313